Physician profile
Christopher Kurz
NPI 1629041058
$1,920.70
in general payments reported to CMS, 2019-2025
22 companies · $569 in 2025
The $569 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $21.43 · 2021: $12.74 · 2022: $191 · 2023: $347 · 2024: $444 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,360.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $235.72 | 2022-2025 | Cequa |
| Amgen INC. | $198.18 | 2024-2025 | Tepezza |
| Allergan, INC. | $195.77 | 2019-2022 | |
| Dompe US, INC. | $176.09 | 2019-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $171.26 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $164.60 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $160.47 | 2024-2025 | Envista Envy, Miebo, Xiidra |
| Abbvie INC. | $123.11 | 2024-2025 | |
| Harrow Eye, LLC | $68.75 | 2024-2025 | Vevye |
| Carl Zeiss Meditec Cataract Technology INC. | $57.17 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $44.04 | 2023-2025 | Acthar |
| Alcon Vision LLC | $43.02 | 2023-2025 | Clareon |
| Kala Pharmaceuticals, INC. | $40.78 | 2019 | |
| Biotissue Holdings INC. | $39.46 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $39.44 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $37.91 | 2025 | Rayone Aspheric, Rayone Spheric, Rayner Cataract Set 1 |
| Aerie Pharmaceuticals, INC. | $27.09 | 2019 | |
| Thea Pharma INC. | $23.98 | 2025 | Iyuzeh |
| Oyster Point Pharma, INC. | $22.52 | 2023 | Tyrvaya |
| Astellas Pharma US INC | $20.74 | 2024 | Izervay |
| Johnson & Johnson Surgical Vision, INC. | $15.67 | 2023 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Shire North American Group INC | $14.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kurz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.